Fang Jing
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fang Jing has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Chen Defang
College of Animal Science and Technology, Sichuan Agriculture University, Chengdu, China
1 shared publicationHua Zhang
Institute of Liver Diseases, Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Shanghai 201203, China; Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai 201203, China
1 shared publication- Jiamei Chen
Institute of Liver Diseases, Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
1 shared publication - Jiaqiang Deng
Key Laboratory of Bio-Resources and Eco-Environment of Ministry of Education, College of Life Sciences, Sichuan University, Chengdu 610065, China
1 shared publication - Kaiyu Wang
Department of Basic Veterinary, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, China
1 shared publication Lai Weimin
College of Veterinary Medicine, Sichuan Agriculture University, Chengdu, China
1 shared publication
Latest Publications
- Open Access
- 30 December 2023
- Published by Elsevier in Phytomedicine
- Vol. 124, 155330
Schisantherin A protects hepatocyte via upregulating DDAH1 to ameliorate liver fibrosis in mice
- 30 December 2023
- Published by Elsevier in Phytomedicine
- Vol. 124, 155330
Open AccessSchisantherin A protects hepatocyte via upregulating DDAH1 to ameliorate liver fibrosis in mice
- Open Access
- 1 January 2018
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2018 (1) , 7579808
Subinhibitory Concentrations of Prim‐O‐Glucosylcimifugin Decrease the Expression of Alpha‐Hemolysin in Staphylococcus aureus (USA300)
Staphylococcus aureus (S. aureus), an important opportunistic pathogen in human and animal, causes a series of diseases in the impairing of immunity of host and even then death. Alpha‐hemolysin (Hla), a primary virulence factor, plays a major role in the pathogenic progress of S. aureus, especially in pneumonia. Prim‐O‐glucosylcimifugin (POG), a nature chromone compound, is an active ingredient in many Chinese Medicines. In this study, POG investigated the inhibitory effect of the secretion of Hla in S. aureus strain USA300 at the subinhibitory concentrations. The hemolysis assays and western blotting assays showed that POG can decrease the production of Hla in the USA300 growth cell cultures in a dose‐dependent manner. The results of RT‐PCR revealed that reduction of Hla was related to inhibit the transcription of hla and RNAIII. In the cells experiment, POG was proved to protect A549 cells from Hla‐medicated injury. In conclusion, POG was shown the capacity of decreased the production of S. aureus Hla. POG can be developed as a candidate agent to treat S. aureus infections against Hla.
- 1 January 2018
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2018 (1) , 7579808
Open AccessSubinhibitory Concentrations of Prim‐O‐Glucosylcimifugin Decrease the Expression of Alpha‐Hemolysin in Staphylococcus aureus (USA300)
Staphylococcus aureus (S. aureus), an important opportunistic pathogen in human and animal, causes a series of diseases in the impairing of immunity of host and even then death. Alpha‐hemolysin (Hla), a primary virulence factor, plays a major role in the pathogenic progress of S. aureus, especially in pneumonia. Prim‐O‐glucosylcimifugin (POG), a nature chromone compound, is an active ingredient in many Chinese Medicines. In this study, POG investigated the inhibitory effect of the secretion of Hla in S. aureus strain USA300 at the subinhibitory concentrations. The hemolysis assays and western blotting assays showed that POG can decrease the production of Hla in the USA300 growth cell cultures in a dose‐dependent manner. The results of RT‐PCR revealed that reduction of Hla was related to inhibit the transcription of hla and RNAIII. In the cells experiment, POG was proved to protect A549 cells from Hla‐medicated injury. In conclusion, POG was shown the capacity of decreased the production of S. aureus Hla. POG can be developed as a candidate agent to treat S. aureus infections against Hla.